Open AccessSurvival and glycemic control in patients with coexisting lymphoma and diabetes: a case–control analysis
Author(s) -
Bria J Rice,
Matthew Buras,
Heidi E. Kosiorek,
Kyle Coppola,
Shailja B Amin,
Patricia M. Verona,
Curtiss B. Cook,
Nina J. Karlin
Publication year - 2021
Publication title -
future science oa
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.825
H-Index - 23
ISSN - 2056-5623
DOI - 10.2144/fsoa-2020-0100
Subject(s) - glycemic , medicine , diabetes mellitus , lymphoma , survival analysis , oncology , gastroenterology , endocrinology
Aim: We examined the effect of diabetes on survival in patients with lymphoma and the effect of lymphoma on glycemic control. Patients & methods: Patients with lymphoma with and without diabetes (2005–2016) were retrospectively identified and matched 1:1. Overall survival and progression-free survival were estimated by the Kaplan–Meier method. Hemoglobin A 1c (HbA 1c ) and glucose levels during the year after cancer diagnosis were compared by mixed models. Results: For patients with diabetes, mean HbA 1c during the year after lymphoma diagnosis was 6.7%. Estimated 5-year progression-free survival for patients with versus without diabetes was 63% (95% CI: 53–76%) versus 58% (95% CI: 46–71%) (p = 0.42). Conclusion: Lymphoma and its treatment did not affect glycemic control. Diabetes did not decrease lymphoma-specific survival.